Formulation comparisons require more than selecting the largest reported exposure ratio. The dose, baseline correction, and analysis plan determine what that ratio means. Primary report
Study snapshot
A 2026 pilot compared three oral formulations in a randomized crossover study of 14 healthy adults. The micellar preparation produced greater baseline-adjusted whole-blood exposure than the standard preparation. Administered amounts were unequal, so the report also presented dose-normalized comparisons. Its separate 30-day safety extension was single-arm. Primary report.
The report acknowledged that participant blinding could not be guaranteed because formulations differed in capsule type. It also disclosed commercial relationships and a pending formulation patent. These details do not invalidate the measurements, but they matter when assessing the independence and reproducibility of a formulation claim.
Our appraisal: three distinctions control the claim
First, a dose-normalized comparison is an analytical adjustment, not another directly administered treatment arm. Its interpretation depends on assumptions about how exposure changes with dose. Readers should not mix adjusted and unadjusted ratios as if they answered the same question.
Second, incremental exposure measures change above a baseline. It is not identical to total exposure or a clinical benefit. A higher value can support a formulation-specific pharmacokinetic conclusion without establishing superior health outcomes.
Third, retrospective registration cannot provide the same prospective record of intended endpoints as registration before enrollment. It does not prove selective reporting, but it limits what the registry can verify about prespecification.
The short, uncontrolled safety phase likewise cannot establish rare-event or long-term safety. Review should inspect the dose-response assumptions, sequence effects, handling of baseline variation, and sponsor relationships. Results from these specific formulations must not be generalized to all products using micellar or liposomal terminology. This is a formulation study, not evidence of disease prevention.
Frequently asked questions
Were all administered doses identical?
No.
Is dose normalization a separate randomized intervention?
No. It is an analytical adjustment.
What does incremental exposure reference?
The analysis adjusts the measured response relative to baseline.
Was registration prospective to study conduct?
There is also an unresolved chronology discrepancy. The paper describes follow-up ending in June 2023, whereas the current registry lists completion in December 2025. The record was first posted in April 2024, after the listed start. The sources therefore do not establish a consistent prospective timeline for all reported work. Trial registry.
A registry discrepancy is not proof of misconduct. It is a reason to avoid stronger claims about prespecification until the study phases and amendments are reconciled. A registered identifier alone does not establish that every analysis was fixed before data collection.
Was the safety extension placebo controlled?
No. It was single arm.
Does higher exposure establish better health outcomes?
No.
What is the main review priority?
Keep actual-dose results, adjusted results, prespecification limits, and clinical uncertainty separate.